Logo

Palvella Therapeutics Expands Partnership with Ligand Pharmaceuticals to Accelerate P-III development of Qtorin Rapamycin

Share this
Palvella

Palvella Therapeutics Expands Partnership with Ligand Pharmaceuticals to Accelerate P-III development of Qtorin Rapamycin

Shots:

  • Under the terms Palvella is qualified to receive up front payment of $5M from Ligand & in exchange, Ligand's existing tiered royalty on global commercial sales of Qtorin rapamycin was raised to 8.0% to 9.8%
  • Furthermore, Ligand gained the option to acquire a single-digit royalty on each new topical product developed from Palvella's QTORIN platform, with the ability to exercise this option in the future.
  • Qtorin rapamycin, Palvella's primary candidate, is a novel 3.9% anhydrous gel designed for treating Microcystic Lymphatic Malformations and skin diseases linked to mTOR pathway overactivation. It has received FDA’s BTD, FTD & ODD for Microcystic LMs & FTD for the prevention of BCCs in Gorlin Syndrome

Ref: Yahoo Finance | Image: Palvella Therapeutics

Related News:- Ligand Purchases Palvella's Royalty Rights and Milestone Payments of PTX-022 for Pachyonychia Congenita

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Kritika Jha

Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions